MIPS is world leader for Highly-Cited researchers in pharmacology and toxicology
10 March 2016
The 2015 list of Highly Cited (HiCi) researchers has entrenched the Monash Institute of Pharmaceutical Sciences (MIPS) as one of the world's leading centres of research in its field.
More researchers from MIPS were listed as HiCi researchers in Pharmacology and Toxicology than from any other university or institute in the world. Monash University was well represented in the 2015 HiCi list with 11 researchers, with an unprecedented 6 of these HiCi researchers from MIPS.
The HiCi list, released by Thomson Reuters, is a measure of research impact, identifying those researchers whose work has had the greatest influence on their peers. The 2015 list recognises researchers that published the largest number of Highly Cited papers within a discipline between 2003 and 2013. Highly cited papers are defined as those that rank in the top 1% by citations for field and publication year.
In addition to individual recognition, HiCi performance is a key indicator used to rank the top research universities in the Academic Ranking of World Universities, issued by Shanghai Jiao Tong University.
The six MIPS researchers who were designated HiCi are:
- Professor Chris Porter, who is addressing the poor oral absorption of new drug candidates, and developing new drug delivery systems to enhance the activity and reduce adverse effects of existing medicines and new drug candidates.
- Professor Arthur Christopoulos, who is working to end the reign of "blunt hammer" medicines. By targeting previously unappreciated drug recognition sites in the body, he and his colleagues are developing more potent and selective medicines to offer better treatment of schizophrenia and diabetes. This is the second time he has achieved the HiCi status.
- Professor Colin Pouton, who is undertaking research in drug discovery and drug delivery and has a particular interest in neurological and neurodegenerative diseases such as Parkinson's and Alzheimer's disease.
- Professor Roger Nation and Professor Jian Li, who are researching solutions to the increasing problem of multidrug-resistant, "superbug" bacteria. Their research into the polymyxin group of antibiotics is already guiding development of new antibiotic dosage regimens for critically ill patients. Professor Li is also leading new initiatives in the field of systems microbiology to provide new insights into antibiotic drug design.
- Professor Bill Charman, who undertakes research in the fields of drug discovery, drug delivery and new medicine development. He is also the Director of MIPS.
The HiCi success comes on the back of success in the most recent round of the Excellence in Research for Australia (ERA) rankings. Monash achieved the highest possible score of "5" (meaning its research was well above world standard) in the research discipline areas of Pharmacology and Pharmaceutical Sciences, Medicinal and Biomolecular Chemistry, and Nanotechnology.